Malini D Sur, MD, FACS

GI/HPB surgical oncologist @NorthsideHosp Cancer Institute | I sing because I’m happy | Tweets mine

[Malini D Sur, MD, FACS @MaliniDSurMD]

Thank you to ⁦@NehaPathakMD⁩ ⁦@WebMD⁩ for inviting me to this podcast to raise awareness for #pancreaticcancerawarenessmonth ⁦@PanCAN⁩ ⁦@lustgartenfdn⁩ https://t.co/HLEHV2eZl8

[Malini D Sur, MD, FACS @MaliniDSurMD]

https://t.co/iJohmA3flg

[Malini D Sur, MD, FACS @MaliniDSurMD]

@SyedAAhmad5 @BJSurgery If a patient needs a j tube prior to Whipple, should they be getting a Whipple at all?

[Nicholas Hornstein @GIMedOnc]

#GI26
KEYNOTE-937 is a letdown, but the story feels familiar 😕🩸

Phase 3 KEYNOTE-937 tested pembrolizumab after surgical resection or local ablation for HCC. This was the long-awaited attempt to bring IO into the adjuvant setting after cure-intent therapy.

📉 The results
Median RFS 46 vs 45 months
4-year RFS rate 50 vs 50 percent

No separation. No late tail. No signal.

🧠 Historical context matters
We’ve now seen this movie before. IMBRAVE-050 also failed to meaningfully move the needle in the adjuvant HCC space. As frustrating as this is, it’s becoming clear that simply dropping IO after surgery is not enough.

🧐 Takeaway
Disappointing, but not totally unexpected. The biology is telling us something. If we want to change outcomes in HCC, the action is likely earlier.

It’s time to double down on neoadjuvant and perioperative strategies, where immune priming and tumor antigen exposure may actually matter.

@OncoAlert @TheGutOncLab

[JAMA Oncology @JAMAOnc]

Gastric cancer is the fifth most diagnosed #cancer and the fifth leading cause of cancer-related deaths worldwide.

This @JAMA_current Review summarizes the epidemiology, pathophysiology, diagnosis, and management of #GastricCancer.

https://t.co/QxD8h2lXuT

[Malini D Sur, MD, FACS @MaliniDSurMD]

@DrBloodandGuts These are devastating cases.

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🧬 PRRT in pheochromocytoma/paraganglioma (mPPGL)
📊 ORR 27% | DCR 73%
⏳ mPFS 26.9 mo | mOS 54.8 mo
💊 Symptom improvement 67% | HTN control 87%
⚠️ Mostly G1–2 hematologic toxicity
➡️ PRRT appears feasible, well tolerated, and clinically meaningful in mPPGL
🔗 https://t.co/y76h1D5EiC
@OncoAlert

[Nieves Martinez Lago MD PhD @DraMartinezLago]

🦠➡️🫁 H. pylori eradication & pancreatic cancer risk

🔍 Nordic cohort (>660k pts; up to 24y follow-up)
⬆️ Risk in first 1–5y post-eradication (SIR 1.14)
⬇️ Declines thereafter, normalizing by 6–10y
🧩 Supports a potential preventive role in long-term pancreatic cancer risk
🔗 https://t.co/tZY6yCDVm3
@OncoAlert

[Annals of Gastroenterological Surgery @surgery81261]

Robotic-assisted rectal cancer surgery is associated with superior short- and long-term outcomes, a large-scale study finds.📈
Compared to open and laparoscopic procedures, robot-assisted surgery had the lowest complication and mortality rates, the shortest hospital stays, and the highest 5-year overall survival and relapse-free survival.🇯🇵
https://t.co/vifRLZCcvS
#colorectalresearch #colorectalsurgery #AGSurg #SoMe4Surgery
@SWexner @juliomayol

[Annals of Surgical Oncology @AnnSurgOncol]

Featured: Transplant Oncology—A New Frontier in #LiverCancer Care @LYohanathan

https://t.co/tm5fSi2Vux

@NabeelZafarMD
@SyedAAhmad5
@SocSurgOnc

[Malini D Sur, MD, FACS @MaliniDSurMD]

@Gut_BMJ I applaud the effort at studying this important question! But worry that lumping together lap, robotic, and open GJ considerably weakens the conclusions.

[Arndt Vogel @ArndtVogel]

Precision medicine strategy in pancreatic ductal adenocarcinoma
@ESMO_Open
https://t.co/8giC5QAJen
🔎342 pts
👉20% of pts with 🎯alterations, including olaparib (BRCA2), trastuzumab (HER2), and KRAS G12C inhibitors
👉MMT with significant survival benefit
@myESMO

[Mark Yarchoan @MarkYarchoan]

I’m all for innovation, but data matter.
I do not understand the hype around #histotripsy.
Worse local control. More toxicity.
How is this progress?

[Syed A. Ahmad @SyedAAhmad5]

FDA Approves Durvalumab With FLOT for Resectable Gastric-GEJ Adenocarcinoma https://t.co/6fgi2se19a

[Bassam Sonbol @sonbol_bassam]

FDA just approved peri-op durvalumab+ FLOT for resectable gastric/GEJ cancer based on MATTERHORN 👏 Huge wins for patients, especially PD-L1+ (which was ~90% of the trial). Congrats to investigators
But one important caveat before we call it a blanket standard for all comers...🧵

[Malini D Sur, MD, FACS @MaliniDSurMD]

I had a walk-in follow up visit during a busy clinic this week. For a second I worried there was an urgent clinical problem. Instead they came to deliver this gorgeous gift. An important lesson to stop & remember the privilege of our profession. @SocSurgOnc @AHPBA

[ASCO @ASCO]

5th Plenary #ASCO25: #MATTERHORN Ph III, Durvalumab + FLOT—>✂️—>Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca.

- 2yr EFS 67% vs 59% (HR: 0.71). Improvement regardless of PDL1
- 2yr OS 76% vs 70%. mOS NR
- Rate of✂️& number of FLOT similar in both arms
- D-FLOT new SoC!

[Malini D Sur, MD, FACS @MaliniDSurMD]

Awaiting your reply @AetnaHelp

[Malini D Sur, MD, FACS @MaliniDSurMD]

Back on Twitter because @Aetna is denying HIPEC for my patient with peritoneal metastases from colorectal cancer - a well established standard of care in the United States for fit patients with reasonable PCI. I cannot even reach a physician to speak with.

[Malini D Sur, MD, FACS @MaliniDSurMD]

@AetnaHelp Followed. Waiting for reply.

[Victoria Brownworth @VABVOX]

As someone gravely ill with a brutal #cancer I want to say this to my fellow Americans: You only have one life. I urge you to spend it loving and caring, not hating and filled with grievance. Every day we have the chance to start over, to be better, to lift others up. Do that.